{"id":"blu-5937","safety":{"commonSideEffects":[{"rate":null,"effect":"Taste disturbance"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL5095035","moleculeType":"Small molecule","molecularWeight":"458.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"P2X3 receptors are ion channels expressed on nociceptive (pain-sensing) neurons that mediate acute and chronic pain signals. By antagonizing P2X3, BLU-5937 reduces the transmission of pain signals from peripheral nerves to the central nervous system. This mechanism is particularly relevant for conditions involving visceral and neuropathic pain.","oneSentence":"BLU-5937 is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:29.625Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic cough"},{"name":"Refractory chronic cough"}]},"trialDetails":[{"nctId":"NCT05600777","phase":"PHASE3","title":"A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough","status":"RECRUITING","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2022-12-05","conditions":"Cough, Refractory Chronic Cough","enrollment":975},{"nctId":"NCT05599191","phase":"PHASE3","title":"A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2022-10-25","conditions":"Cough, Refractory Chronic Cough","enrollment":825},{"nctId":"NCT05570539","phase":"PHASE1","title":"Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2022-10-07","conditions":"Cough, Healthy","enrollment":30},{"nctId":"NCT05959447","phase":"PHASE1","title":"Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2023-07-26","conditions":"Cough, Healthy","enrollment":45},{"nctId":"NCT05899829","phase":"PHASE1","title":"Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2023-06-21","conditions":"Cough, Healthy","enrollment":42},{"nctId":"NCT06179537","phase":"PHASE1","title":"Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2021-08-06","conditions":"Healthy","enrollment":34},{"nctId":"NCT04693195","phase":"PHASE2","title":"A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2020-12-09","conditions":"Chronic Pruritus, Atopic Dermatitis","enrollment":142},{"nctId":"NCT05244759","phase":"PHASE1","title":"Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2020-08-25","conditions":"Healthy","enrollment":6},{"nctId":"NCT04678206","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2020-12-07","conditions":"Refractory Chronic Cough","enrollment":310},{"nctId":"NCT03979638","phase":"PHASE2","title":"A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough","status":"TERMINATED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2019-07-10","conditions":"Chronic Refractory Cough","enrollment":68},{"nctId":"NCT03638180","phase":"PHASE1","title":"BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2018-07-09","conditions":"Cough","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Camlipixant"],"phase":"phase_3","status":"active","brandName":"BLU-5937","genericName":"BLU-5937","companyName":"Bellus Health Inc. - a GSK company","companyId":"bellus-health-inc-a-gsk-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BLU-5937 is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons. Used for Chronic cough, Refractory chronic cough.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}